Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Gastroenterology

Volumn 159, Issue 2, 2020, Pages 481-491.e3

  Brenner, Erica J ^a   Ungaro, Ryan C ^b   Gearry, Richard B ^c   Kaplan, Gilaad G ^d   Kissous Hunt, Michele ^e   Lewis, James D ^f   Ng, Siew C ^g   Rahier, Jean Francois ^h   Reinisch, Walter ⁱ   Ruemmele, Frank M ^j   Steinwurz, Flavio ^k   Underwood, Fox E ^d   Zhang, Xian ^a   Colombel, Jean Frederic ^b   Kappelman, Michael D ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF CALGARY   (Canada)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

more..

Author keywords

COVID 19; Crohn's Disease; Inflammatory Bowel Disease; Ulcerative Colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CHLOROQUINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; IMMUNOLOGIC AGENT; INTEGRIN INHIBITOR; INTERLEUKIN 12 INHIBITOR; INTERLEUKIN 23 INHIBITOR; JANUS KINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OSELTAMIVIR; PROTEIN INHIBITOR; REMDESIVIR; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CHINA; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMORBIDITY; CORONAVIRUS DISEASE 2019; CROHN DISEASE; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FETUS; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INTENSIVE CARE UNIT; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEWBORN; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED STATES; VERY ELDERLY; BETACORONAVIRUS; CORONAVIRUS INFECTION; HEALTH SURVEY; HOSPITALIZATION; INTENSIVE CARE; MIDDLE AGED; MORTALITY; ODDS RATIO; PANDEMIC; REGISTER; RISK FACTOR; VIROLOGY; VIRUS PNEUMONIA;

ADRENAL CORTEX HORMONES; ADULT; AGED; BETACORONAVIRUS; COMORBIDITY; CORONAVIRUS INFECTIONS; CRITICAL CARE; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PANDEMICS; PNEUMONIA, VIRAL; POPULATION SURVEILLANCE; REGISTRIES; RESPIRATION, ARTIFICIAL; RISK FACTORS; SULFASALAZINE; TUMOR NECROSIS FACTOR INHIBITORS;

EID: 85086564179     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2020.05.032     Document Type: Article

References (27)

1. Morens, D.M., Daszak, P., Taubenberger, J.K., Escaping Pandora's box - another novel coronavirus. N Engl J Med 382 (2020), 1293–1295.
2. Onder, G., Rezza, G., Brusaferro, S., Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [published online ahead of print March 23, 2020]. JAMA. https://doi.org/10.1001/jama.2020.4683.
3. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print February 24, 2020]. JAMA. https://doi.org/10.1001/jama.2020.2648.
4. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 69 (2020), 382–386.
5. Ng, S.C., Shi, H.Y., Hamidi, N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390 (2018), 2769–2778.
6. Torres, J., Mehandru, S., Colombel, J.F., et al. Crohn's disease. Lancet 389 (2017), 1741–1755.
7. Ungaro, R., Mehandru, S., Allen, P.B., et al. Ulcerative colitis. Lancet 389 (2017), 1756–1770.
8. Lichtenstein, G.R., Loftus, E.V., Isaacs, K.L., et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol 113 (2018), 481–517.
9. Matsuoka, K., Kobayashi, T., Ueno, F., et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 53 (2018), 305–353.
10. Rahier, J.F., Magro, F., Abreu, C., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8 (2014), 443–468.
11. Ananthakrishnan, A.N., McGinley, E.L., Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 7 (2013), 107–112.
12. Kirchgesner, J., Lemaitre, M., Carrat, F., et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155 (2018), 337–346.e10.
13. Long, M.D., Martin, C., Sandler, R.S., et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 108 (2013), 240–248.
14. Ma, C., Lee, J.K., Mitra, A.R., et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 50 (2019), 5–23.
15. Tinsley, A., Williams, E., Liu, G., et al. The incidence of influenza and influenza-related complications in inflammatory bowel disease patients across the United States: 1833. Am J Gastroenterol, 2013, 108.
16. Michot, J.M., Albies, L., Chaput, N., et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol 31 (2020), 961–964.
17. Zhang, X., Song, K., Tong, F., et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Advances 4 (2020), 1307–1310.
18. Guan, W.J., Ni, Z.Y., Hu, Y., et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 382 (2020), 1708–1720.
19. Liang, W., Guan, W., Chen, R., Wang, W., et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21 (2020), 335–337.
20. Mazza, S., Sorce, A., Peyvandi, F., et al. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut 69 (2020), 1148–1149.
21. Jenks, G., The data model concept in statistical mapping. Int Yearb Carto 7 (1967), 186–190.
22. Turner, D., Huang, Y., Martín-de-Carpi, J., et al. COVID-19 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr 70 (2020), 727–733.
23. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 41 (2020), 145–151.
24. Centers for Disease Control and Prevention. Coronavirus Disease 2019 Cases in U.S. Available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html Published April 16, 2020. Accessed April 17, 2020.
25. Centers for Disease Control and Prevention. Provisional Death Counts for Coronavirus Disease (COVID-19). Available at: https://www.cdc.gov/nchs/nvss/vsrr/COVID19/ Published April 17, 2020. Accessed April 17, 2020.
26. Russell, C.D., Millar, J.E., Baillie, J.K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
27. Feldmann, M., Maini, R.N., Woody, J.N., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395 (2020), 1407–1409.